As compared to conventional, stand-alone clinical trials in advanced non-small cell lung cancer (NSCLC), the biomarker-driven Lung Cancer Master Protocol (Lung-MAP) has enrolled higher percentages of ...
This protocol is an extension to: Nat. Protoc. 10, 1643–1669 (2015); doi:10.1038/nprot.2015.103; published online 01 October 2015 RNAs play key roles in many ...
A prototype service utilising satellites for mapping forests to aid compliance with the Kyoto Protocol has been endorsed by end users from European countries one environmental ministry representative ...
Lung Cancer Master Protocol (Lung-MAP), a public-private partnership, established infrastructure for conducting a biomarker-driven master protocol in molecularly targeted therapies. We compared ...
MAP Pharmaceuticals Reaches Agreement with FDA on Special Protocol Assessment for MAP0004 Phase 3 Clinical Trial in Patients With Migraine MOUNTAIN VIEW, Calif., Jan 16, 2008 -- MAP Pharmaceuticals, ...
High-quality evidence is what we use to guide medical practice. The standard approach to generating this evidence — a series of clinical trials, each investigating one or two interventions in a single ...
Clonal Hematopoiesis as a Molecular Risk Factor for Doxorubicin-Induced Cardiotoxicity: A Proof-of-Concept Study Lung Cancer Master Protocol (Lung-MAP), a public-private partnership, established ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results